Paul Weinberger1,2,3, Sithara Raju Ponny1, Hongyan Xu4, Shan Bai1, Robert Smallridge5, John Copland6, Ashok Sharma1,4. 1. 1 Center for Biotechnology and Genomic Medicine, Medical College of Georgia at Augusta University , Augusta, Georgia . 2. 2 Department of Otolaryngology, Medical College of Georgia at Augusta University , Augusta, Georgia . 3. 3 Augusta University Cancer Center, Medical College of Georgia at Augusta University , Augusta, Georgia . 4. 4 Department of Biostatistics and Epidemiology, Medical College of Georgia at Augusta University , Augusta, Georgia . 5. 5 Division of Endocrinology, Mayo Clinic , Jacksonville, Florida. 6. 6 Department of Cancer Biology, Mayo Clinic , Jacksonville, Florida.
Abstract
BACKGROUND: Anaplastic thyroid carcinoma (ATC) accounts for only 3% of thyroid cancers, yet strikingly, it accounts for almost 40% of thyroid cancer deaths. Currently, no effective therapies exist. In an effort to identify ATC-specific therapeutic targets, we analyzed global gene expression data from multiple studies to identify ATC-specific dysregulated genes. METHODS: The National Center for Biotechnology Information Gene Expression Omnibus database was searched for high-throughput gene expression microarray studies from human ATC tissue along with normal thyroid and/or papillary thyroid cancer (PTC) tissue. Gene expression levels in ATC were compared with normal thyroid or PTC using seven separate comparisons, and an ATC-specific gene set common in all seven comparisons was identified. We investigated these genes for their biological functions and pathways. RESULTS: There were three studies meeting inclusion criteria, (including 32 ATC patients, 69 PTC, and 75 normal). There were 259 upregulated genes and 286 downregulated genes in ATC with at least two-fold change in all seven comparisons. Using a five-fold filter, 36 genes were upregulated in ATC, while 40 genes were downregulated. Of the 10 top globally upregulated genes in ATC, 4/10 (MMP1, ANLN, CEP55, and TFPI2) are known to play a role in ATC progression; however, 6/10 genes (TMEM158, CXCL5, E2F7, DLGAP5, MME, and ASPM) had not been specifically implicated in ATC. Similarly, 3/10 (SFTA3, LMO3, and C2orf40) of the most globally downregulated genes were novel in this context, while 7/10 genes (SLC26A7, TG, TSHR, DUOX2, CDH1, PDE8B, and FOXE1) have been previously identified in ATC. We experimentally validated a significant correlation for seven transcription factors (KLF16, SP3, ETV6, FOXC1, SP1, EGFR1, and MAFK) with the ATC-specific genes using microarray analysis of ATC cell lines. Ontology clustering of globally altered genes revealed that "mitotic cell cycle" is highly enriched in the globally upregulated gene set (44% of top upregulated genes, p-value <10-30). CONCLUSIONS: By focusing on globally altered genes, we have identified a set of consistently altered biological processes and pathways in ATC. Our data are consistent with an important role for M-phase cell cycle genes in ATC, and may provide direction for future studies to identify novel therapeutic targets for this disease.
BACKGROUND:Anaplastic thyroid carcinoma (ATC) accounts for only 3% of thyroid cancers, yet strikingly, it accounts for almost 40% of thyroid cancer deaths. Currently, no effective therapies exist. In an effort to identify ATC-specific therapeutic targets, we analyzed global gene expression data from multiple studies to identify ATC-specific dysregulated genes. METHODS: The National Center for Biotechnology Information Gene Expression Omnibus database was searched for high-throughput gene expression microarray studies from human ATC tissue along with normal thyroid and/or papillary thyroid cancer (PTC) tissue. Gene expression levels in ATC were compared with normal thyroid or PTC using seven separate comparisons, and an ATC-specific gene set common in all seven comparisons was identified. We investigated these genes for their biological functions and pathways. RESULTS: There were three studies meeting inclusion criteria, (including 32 ATC patients, 69 PTC, and 75 normal). There were 259 upregulated genes and 286 downregulated genes in ATC with at least two-fold change in all seven comparisons. Using a five-fold filter, 36 genes were upregulated in ATC, while 40 genes were downregulated. Of the 10 top globally upregulated genes in ATC, 4/10 (MMP1, ANLN, CEP55, and TFPI2) are known to play a role in ATC progression; however, 6/10 genes (TMEM158, CXCL5, E2F7, DLGAP5, MME, and ASPM) had not been specifically implicated in ATC. Similarly, 3/10 (SFTA3, LMO3, and C2orf40) of the most globally downregulated genes were novel in this context, while 7/10 genes (SLC26A7, TG, TSHR, DUOX2, CDH1, PDE8B, and FOXE1) have been previously identified in ATC. We experimentally validated a significant correlation for seven transcription factors (KLF16, SP3, ETV6, FOXC1, SP1, EGFR1, and MAFK) with the ATC-specific genes using microarray analysis of ATC cell lines. Ontology clustering of globally altered genes revealed that "mitotic cell cycle" is highly enriched in the globally upregulated gene set (44% of top upregulated genes, p-value <10-30). CONCLUSIONS: By focusing on globally altered genes, we have identified a set of consistently altered biological processes and pathways in ATC. Our data are consistent with an important role for M-phase cell cycle genes in ATC, and may provide direction for future studies to identify novel therapeutic targets for this disease.
Authors: A Fiumara; A Belfiore; G Russo; E Salomone; G M Santonocito; O Ippolito; R Vigneri; P Gangemi Journal: J Clin Endocrinol Metab Date: 1997-05 Impact factor: 5.958
Authors: Darya Buehler; Heather Hardin; Weihua Shan; Celina Montemayor-Garcia; Patrick S Rush; Sofia Asioli; Herbert Chen; Ricardo V Lloyd Journal: Mod Pathol Date: 2012-08-17 Impact factor: 7.842
Authors: Vlasta Sykorova; Sarka Dvorakova; Josef Vcelak; Eliska Vaclavikova; Tereza Halkova; Daniela Kodetova; Petr Lastuvka; Jan Betka; Petr Vlcek; Martin Reboun; Rami Katra; Bela Bendlova Journal: Anticancer Res Date: 2015-04 Impact factor: 2.480
Authors: Christina A von Roemeling; Laura A Marlow; Anthony B Pinkerton; Angela Crist; James Miller; Han W Tun; Robert C Smallridge; John A Copland Journal: J Clin Endocrinol Metab Date: 2015-02-12 Impact factor: 5.958
Authors: C Montero-Conde; J M Martín-Campos; E Lerma; G Gimenez; J L Martínez-Guitarte; N Combalía; D Montaner; X Matías-Guiu; J Dopazo; A de Leiva; M Robledo; D Mauricio Journal: Oncogene Date: 2007-09-17 Impact factor: 9.867
Authors: Ahmed S K Al-Khafaji; Paschalia Pantazi; Amelia Acha-Sagredo; Andrew Schache; Janet M Risk; Richard J Shaw; Triantafillos Liloglou Journal: Oncol Lett Date: 2020-01-23 Impact factor: 2.967
Authors: Débora Cabral de Carvalho Corrêa; Indhira Dias Oliveira; Bruna Mascaro Cordeiro; Frederico Adolfo Silva; Maria Teresa de Seixas Alves; Nasjla Saba-Silva; Andrea Maria Capellano; Patrícia Dastoli; Sergio Cavalheiro; Silvia Regina Caminada de Toledo Journal: Childs Nerv Syst Date: 2020-06-26 Impact factor: 1.532